Eva Renee Barnett - Oct 11, 2022 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role: Chief Financial Officer
Signature: /s/ Eva Renee Barnett
Stock symbol: IMVT
Transactions as of: Oct 11, 2022
Transactions value $: -$118,000
Form type: 4
Date filed: 10/13/2022, 04:20 PM
Previous filing: Aug 19, 2022
Next filing: Jan 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMVT	Common Stock	Sale	-$118K	-12.5K	-4.38%	$9.44	273K	Oct 11, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 25% of these RSUs vested on October 4, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 - $9.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Content

On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 25% of these RSUs vested on October 4, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 - $9.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.